Newman R P, LeWitt P A, Shults C, Bruno G, Foster N L, Chase T N, Calne D B
Clin Neuropharmacol. 1985;8(4):328-33.
As with parkinsonism, certain dystonias may involve disturbances in dopaminergic neurotransmission. The effects of bromocriptine, 18-150 mg/day (mean, 72.5), were studied in 15 patients with a variety of dystonic disorders, using a double-blind, crossover format. Of the 13 patients completing several weeks of medication, seven improved more than 10% and two worsened, on clinical ratings, while five recognized improvement in disability. Dopaminomimetic agents such as bromocriptine, used in the dose range effective for treating parkinsonism, may yield symptomatic improvement with several patterns of dystonia.
与帕金森症一样，某些肌张力障碍可能涉及多巴胺能神经传递紊乱。采用双盲交叉试验形式，对15例患有各种肌张力障碍疾病的患者研究了溴隐亭（每日18 - 150毫克，平均72.5毫克）的疗效。在完成数周药物治疗的13例患者中，根据临床评分，7例改善超过10%，2例病情恶化，5例自觉残疾状况有所改善。像溴隐亭这样的拟多巴胺药物，在治疗帕金森症的有效剂量范围内使用时，可能会使几种类型的肌张力障碍症状得到改善。
